A recent public health campaign in Spain, spearheaded by pharmaceutical giant Novo Nordisk, has drawn attention and sparked debate. The campaign features posters with the stark message "Obesity Can Kill," encouraging open dialogue about obesity. However, the initiative's direct link to Novo Nordisk, known for its weight-loss drug Ozempic, has prompted questions from some members of the public. One social media user, @alicewonderbear, highlighted the campaign, expressing concern over the pharmaceutical company's approach. "Instead of helping to combat something many people face with good healthy habits and sport, they want you to inject something," she stated in a video, referencing the drug Ozempic. She further claimed that the drug is currently being linked to severe side effects, including blindness, and can cause immunity if one becomes diabetic in the future. These specific claims regarding side effects and immunity require independent verification from medical and regulatory bodies. Novo Nordisk maintains that its campaigns aim to raise awareness about obesity as a serious health condition. The company's products, including Ozempic, are approved for specific medical uses and are subject to strict regulatory oversight, with detailed information on potential side effects available in patient leaflets. The ongoing public discourse underscores the complexities of health promotion, corporate responsibility, and public perception in the pharmaceutical industry.
La iniciativa de Novo Nordisk, que pretende hablar “sin filtros” al señalar que es una enfermedad, se topa con el rechazo en redes y sacude el debate…
Novo Nordisk’s campaign, which aims to speak ‘without filters’ by declaring obesity a disease, has been strongly criticized on social media: ‘It’s in…
